Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Specific Aims
The specific aims of the study are:
- Primary Objective: To assess the effect of alemtuzumab on microglial activation in MS
patients. The hypothesis is that alemtuzumab reduces microglial activation in MS, which
may mediate its effect on reducing conversion of RRMS patients to SPMS, and its effects
on cognition, including cognitive fatigue.
- Secondary Objective: To determine the time course of effect of alemtuzumab on microglial
activation. The hypothesis is that alemtuzumab reduces microglial activation at 6 months
after initiation of treatment and this effect persists and is accentuated at 18 years,
i.e. after administration of the second course